AGS Biomarker Study: Plasma NfL and GFAP Levels in 55 Patients

55 patients with Aicardi–Goutières syndrome (AGS) and 55 matched controls had plasma neurofilament light chain and glial fibrillary acidic protein levels measured using single molecule array assays. The dataset, authored by Lisa Wege and last updated in April 2026, includes longitudinal samples from 11 patients before and during JAK inhibitor therapy. Biomarker levels were assessed against clinical severity and interferon scores.

Use Cases

• Modeling the relationship between plasma biomarker levels and clinical disease severity in AGS.
• Analyzing biomarker response to JAK inhibitor therapy based on longitudinal patient data.
• Comparing the sensitivity of neurofilament light chain and glial fibrillary acidic protein against the interferon score.
• Investigating correlations between neuroaxonal and astroglial injury markers in a rare neuroimmunological disorder.

Strengths

• Includes a matched control group of 55 healthy individuals for comparison.
• Longitudinal data from 11 patients captures changes before and during therapy.
• Biomarker levels were measured using single molecule array assays, a sensitive method.

Limitations

• Row count and column-level documentation are unknown, limiting suitability assessment.
• The dataset is small at 810.5 KB, indicating a limited scope.
• Column names and sample data are unavailable; field semantics must be inferred after download.

Provenance

Source

figshare

Collection Method

Plasma samples analyzed using single molecule array assays.

Time Range

Temporal coverage is not specified in the input.

Freshness

Last updated 2026-04-15 05:26:01; freshness should be verified.

Geography

Spatial coverage is not specified in the input.